Christopher Reading - May 30, 2024 Form 4 Insider Report for U S PHYSICAL THERAPY INC /NV (USPH)

Role: Chairman of the Board and CEO, Director
Signature: /s/ Christopher Reading
Stock symbol: USPH
Transactions as of: May 30, 2024
Transactions value $: -$290,754
Form type: 4
Date filed: 5/31/2024, 06:00 PM
Previous filing: May 29, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	USPH	Common Stock	Sale	-$291K	-2.9K	-2.94%	$100.26	95.8K	May 30, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported ($100.26) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $100.00 to $100.90 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2	Includes 32,913 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 3,587 shares on each of July 1, 2024 and October 1, 2024; 3,588 shares on January 1, 2025; 2,887 shares on each April 1, 2025, July 1, 2025, and on October 1, 2025; 2,888 shares on January 1, 2026; 1,637 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 1,638 shares on January 1, 2027; and 1,012 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 1,017 shares on January 1, 2028, if he is an Officer of the Company on those dates.

Content

The price reported ($100.26) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $100.00 to $100.90 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Includes 32,913 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 3,587 shares on each of July 1, 2024 and October 1, 2024; 3,588 shares on January 1, 2025; 2,887 shares on each April 1, 2025, July 1, 2025, and on October 1, 2025; 2,888 shares on January 1, 2026; 1,637 shares on each of April 1, 2026, July 1, 2026, October 1, 2026; 1,638 shares on January 1, 2027; and 1,012 shares on each of April 1, 2027, July 1, 2027, October 1, 2027; and 1,017 shares on January 1, 2028, if he is an Officer of the Company on those dates.